Search

Search Constraints

You searched for: Author/Creator Glintborg, B.

Search Results

2. FRI0103 One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study. (12th June 2018)

3. FRI0275 ONE-YEAR TREATMENT RETENTION OF SECUKINUMAB VERSUS TUMOR NECROSIS FACTOR INHIBITORS IN SPONDYLOARTHRITIS. RESULTS FROM FIVE NORDIC BIOLOGIC REGISTRIES. (2nd June 2020)

4. FRI0283 CO-MEDICATION WITH CSDMARD HAS LITTLE EFFECT ON THE RETENTION OF TNF INHIBITORS IN PSORIATIC ARTHRITIS, RESULTS FROM THE EUROSPA COLLABORATION. (2nd June 2020)

5. FRI0534 PATIENT-REPORTED MEASURES OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS VARY ACROSS THE NORDIC COUNTRIES, RESULTS FROM A NORDIC COLLABORATION. (2nd June 2020)

6. OP0014 COMPARISON OF ANTERIOR UVEITIS OCCURRENCE DURING TREATMENT WITH SECUKINUMAB, ADALIMUMAB, INFLIXIMAB AND ETANERCEPT IN SPONDYLOARTHRITIS. (2nd June 2020)

7. OP0075 Impact of Different Infliximab Dose Regimens on Treatment Response and Drug Survival in 462 Patients with PSA. Results from the Nationwide Registries Danbio and Icebio. (10th June 2014)

8. OP0109 CO-MEDICATION WITH A CONVENTIONAL SYNTHETIC DMARD IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH IMPROVED RETENTION OF TNF INHIBITORS: RESULTS FROM THE EUROSPA COLLABORATION. (2nd June 2020)

9. OP0168 Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: Results from the danish nationwide danbio registry. (23rd January 2014)

10. OP0225 Three Months' Clinical Outcomes from A Nationwide Non-Medical Switch from Originator To Biosimilar Infliximab in Patients with Inflammatory Arthritis. Results from The Danbio Registry. (15th July 2016)